Diagnostic value of SUVmax/ADCmin obtained by 11 C-choline PET/MR in patients with prostate cancer
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3760/cma.j.issn.2095-2848.2016.01.008
   		
        
        	
        		- VernacularTitle:11 C-胆碱P ET/MR SUVmax/ADCmin比值诊断前列腺癌的价值
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Yachao LIU
			        		
			        		;
		        		
		        		
		        		
			        		Yong XU
			        		
			        		;
		        		
		        		
		        		
			        		Aijun LIU
			        		
			        		;
		        		
		        		
		        		
			        		Jiajin LIU
			        		
			        		;
		        		
		        		
		        		
			        		Can LI
			        		
			        		;
		        		
		        		
		        		
			        		Yungang LI
			        		
			        		;
		        		
		        		
		        		
			        		Jiangping GAO
			        		
			        		;
		        		
		        		
		        		
			        		Xu ZHANG
			        		
			        		;
		        		
		        		
		        		
			        		Jiahe TIAN
			        		
			        		;
		        		
		        		
		        		
			        		Baixuan XU
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Prostatic neoplasms;
			        		
			        		
			        		
				        		Tomography,emission-computed;
			        		
			        		
			        		
				        		Magnetic resonance imaging;
			        		
			        		
			        		
				        		Choline;
			        		
			        		
			        		
				        		Carbon radioisotopes
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			Chinese Journal of Nuclear Medicine and Molecular Imaging
	            		
	            		 2016;(1):30-33
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Objective To evaluate the value of SUVmax/ADCmin obtained by 11 C?choline PET/MR imaging in the differential diagnosis of benign and malignant prostate disease. Methods Suspicious prostate cancer patients who underwent PET/MR before transperineal prostate biopsy in People′s Liberation Army General Hospital from April 2014 to January 2015 were observed. Prostate gland was divided into five dis?tricts. A ROI with the diameter of 1 cm was drawn at the highest radioactivity concentration and/or lowest ADC signal area in each district, and SUVmax , ADCmin and SUVmax/ADCmin were then calculated. Taking the pathological results as the gold standard, malignant and benign prostate disease districts were separated. Pearson correlation analysis and two?sample t test were used for statistical analysis. Results Biopsy pathol?ogy showed 9 cases were malignant ( 25 prostate cancer districts, and 20 benign prostate disease districts) , and 6 cases were benign (30 benign prostate disease districts). The SUVmax had a negative correlation with ADCmin( r=-0.521, P<0?05) . The SUVmax/ADCmin of benign and malignant districts was significantly dif?ferent(5.67±3.03 and 13?76±7.13; t=6.9, P<0.01). The ROC AUC for ADCmin, SUVmax and SUVmax/ADCmin were 0?880, 0?809 and 0.898. Using SUVmax/ADCmin of 7.78 as a cutoff, the sensitivity, specificity and accuracy of 11 C?choline PET/MR imaging for differentiating the benign and malignant prostate lesions were 84.0%(21/25), 86.0%(43/50) and 85.3%(64/75), respectively. Conclusions Simultaneous 11C?choline PET/MR could be used for detecting prostate cancer. SUVmax/ADCmin may serve as an effective diag?nostic indicator for differentiating benign and malignant prostate lesions.